HealthcareMid capRs 16,205 crRs 20.2 cr traded a day
Close on 10 September 2026
1,025.65
+0.65%
52-week range58% of the way up
807.651,181.20
Market cap
16,205 cr
P/E (TTM)
46.1×
industry 45×
EPS (TTM)
22.24
Revenue YoY
+17.3%
Q1 FY27
Profit YoY
-45.0%
Net margin
2.5%
-2.9pt vs a year ago
Growth trend
-1.4pt
vs last quarter’s YoY
1 month
+15.2%
Below 52w high
15.2%
RSI (14)
85
overbought
Daily swing
3.1%
average true range
Volume
0.4×
vs 20-day average
Traded
Rs 20 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
Key metrics
each ranked against every stock scanned tonight
Above the 200-day average
Around the median
+7.8%
One-year return
Around the median
-6.0%
Return on capital employed
n/a
Debt to equity
n/a
Profitable quarters, last four
of the last four reported
4 of 4
Cash conversion
cash from operations against reported profit
n/a
Revenue growth, year on year
latest reported quarter
+17.3%
Below the 52-week high
from the highest close of the year
-13.2%
1 week
+12.97%
1 month
+15.16%
3 months
+3.46%
6 months
+19.73%
1 year
−6.00%
The read
written from the numbers on this page
The evidence is mixed4 supporting, 3 against, 1 worth knowing
Supporting
trading 8% above its 200-day average
matches consistently growing and profitable, which has beaten the market by +0.51 points over 20 sessions across 117,484 past signals
4 independent kinds of evidence agree today, which is uncommon
revenue grew 17% year on year in the quarter ending 30 June 2026
Against
down 6% over twelve months
2 of the scans it matches have historically underperformed the market
net margin has narrowed from 6.1% to 2.5% across four quarters
Worth knowing
RSI at 85 is stretched; strong stocks stay stretched for a long time, so this is a note on entry timing, not on direction
What would change this read: a close below 952, its 200-day average.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
from the filings and from the price, with the figure behind every line
Working3
Revenue rose 17.3% year on year, from Rs 1,901 cr to Rs 2,229 cr.
+17.3%Rs 1,901 crRs 2,229 cr
Trading 7.8% above its 200-day average, which is the line most investors use to separate a bull phase from a bear one.
+7.8%
3 different kinds of evidence point at it tonight, not 3 versions of the same one.
3 families
Needs watching3
Net profit -45.0% year on year, Rs 102 cr to Rs 56 cr.
-45.0%Rs 102 crRs 56 cr
Profit grew slower than revenue, -45.0% against +17.3%.
-45.0%+17.3%
Net margin fell from 5.4% to 2.5% this quarter versus last year.
5.4%2.5%
Every figure here is computed — from the company’s own filings, or from its own closing prices. Wording of 2 of these 4 filing lines was drafted by a language model, which is given the figures and may not introduce another — any sentence containing a number that did not come from the filings is discarded before it reaches this page.
How it has performed
price return over each window, beside the median NSE stock over the same days
What the scans say today
7 of 47 matched on 10 Sep
JUBLPHARMA matches 7 of the 47 scans today, across 4 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
JUBLPHARMA trades at 46× trailing earnings, above its median of 33× over this window — 39% more expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Legal / regulatory filings were typically +0.62pt vs the market over the next 5 sessions (n=137) · AGM / EGM filings were typically +0.17pt vs the market over the next 5 sessions (n=8,423) · Order win filings were typically -0.10pt vs the market over the next 5 sessions (n=630)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 17% against the same quarter a year earlier
revenue rose in 3 of the last 4 quarters
Going against it
profit dropped 45% year on year
net margin narrowed from 5.2% to 2.5%
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
30 Jun · consolidated
2,229
86
56
3.57
2.5%
Q4 FY26
31 Mar · consolidated
2,290
176
119
7.55
5.2%
Q3 FY26
31 Dec · consolidated
2,122
94
56
3.52
2.6%
Q2 FY26
30 Sep · consolidated
1,966
190
120
7.59
6.1%
Q1 FY26
30 Jun · consolidated
1,901
154
102
6.49
5.4%
Q4 FY25
31 Mar · consolidated
1,929
206
151
9.71
7.8%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+8.7%
Versus 200-day average+7.8%
Below 52-week high-13.2%
Above 52-week low+27.0%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)84.7
Higher closes in last 55 of 5
Six-month return+19.73%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.11%
Volume versus 20-day0.4x
Median daily turnoverRs 20.2 cr
Peers
Healthcare · 68 classified companies
JUBLPHARMA trades at 46.1× trailing earnings against an industry median of 44.7× across 65 other classified companies in its industry — priced roughly in line with them. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.